News
News Medical on MSN7d
Understanding resistance to EGFR targeted therapies in head and neck cancers and breast cancerA new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...
The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...
In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated ...
Verywell Health on MSN8d
Advances in Upper Gastrointestinal Cancer TreatmentThe latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...
ACROBiosystems has developed a series of specialized proteases for the screening and validation of ADC linkers, focusing on ...
Barchart on MSN3d
ProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?Chronic kidney disease (CKD) is a silent epidemic. In this high-stakes space, biotechnology companies focused on reversing or ...
The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.
By creating artificial aging in mice, researchers at Lund University in Sweden have been able to track the formation of ...
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is characterized by a high rate of metastasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback